Recent Post
Seeking a multi-talented Account Director for award-winning independent health + wellness communications agency, Sydney
VIVA! Communications – a dynamic, award-winning, health + wellness communications agency – is seeking an ambitious and experienced Account Director to join the team in a full-time role. As the exclusive Australian partner of GLOBALHealthPR, our work spans the APAC region across Public health, Pharmaceutical, BioTech, Med-devices, Consumer health and Not-for-Profit sectors. The ideal candidate…
Read MoreHow hearing aids can help protect against dementia
You’ve probably seen your grandma doing crosswords or sudoku on a Sunday morning, and you may be aware that these ‘brain training’ exercises are considered tools to help ward off dementia. But did you know a conversation with your grandma over a cup of tea may be just as important? According to Dementia Australia, people…
Read MoreToday is World Tuberculosis Day
On this day (Friday, March 24) in 1882, Dr. Robert Koch discovered the bacterium that causes tuberculosis (TB), pioneering the path towards a TB-free world. Nowadays, we band together every year on this date to raise awareness of TB, the leading cause of death by infectious disease worldwide. In 2021 alone, TB infected 10.6 million…
Read MoreHappy International Women’s Day!
At VIVA! Communications, we believe in uplifting women and embracing equity in health + wellness. Today we are celebrating International Women’s Day (IWD) – a day that has symbolised the Women’s Rights movement since 1975. This IWD, we are focusing on achieving equitable access to healthcare and equity within the healthcare industry. Health systems and…
Read MoreTick of approval needed for Alzheimer’s disease medication in AUS
There are calls for the Therapeutic Goods Administration (TGA) to greenlight a breakthrough medication with the potential to slow the progression of Alzheimer’s disease. The Federal Drug Administration (FDA) recently approved humanised monoclonal antibody Lecanemab for use in patients with the neurodegenerative disease, in the wake of promising clinical trial outcomes. The medication, marketed as…
Read More